Skip to main content

EHC Encompass Health Corporation

Healthcare

135.90 Close 10/30
Since 2024-12-02 +34.6%
Open
134.53
High
137.27
Low
132.44
Prev close
131.49
Volume
1.8M
Amplitude
3.67%
P/E
21.2
P/B
5.0
Revenue YoY (TTM)
+9.4%
52W 92.77 137.27

Is Encompass Health Corporation a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Good, Growth: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 21.23 56th percentile Pricey
Price / book 5 83th percentile Expensive
Free-cash-flow yield (%) 3.41 60th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good ROE, TTM is Top; FCF margin, TTM is Good.
ROE, TTM (%) 24.03 85th percentile Top
Operating margin, TTM (%) 18.32 69th percentile Good
FCF margin, TTM (%) 7.21 56th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Good All 2 indicators are Good.
Revenue growth, TTM YoY (%) 9.36 59th percentile Good
Diluted EPS growth, TTM YoY (%) 20.98 67th percentile Good
Momentum Good 60-day return is Top; 240-day return is Good.
60-day return (%) 9.07 85th percentile Top
240-day return (%) 20.66 72th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 142,928,127 90th percentile Top
60-day annualized volatility (%) 26.86 30th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Encompass Health Corporation (EHC) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Encompass Health Corporation to every stock like it

AI finds several complementary traits of Encompass Health Corporation across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Encompass Health Corporation

Encompass Health Corporation (EHC) peers and tracking

Watchlist

This page refreshes daily after the close. Add Encompass Health Corporation to your watchlist to track signal changes on your next visit.

Encompass Health Corporation (EHC) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

29 historical occurrences (since 2017-02-21)

Average forward return after 52-week adjusted-price high

20-day: Win 60.7%, Sample 28, Median +2.16%, Excess +0.35%, Beat mkt rate 53.6%

60-day: Win 57.1%, Sample 28, Median +5.29%, Excess +0.19%, Beat mkt rate 53.6%

120-day: Win 71.4%, Sample 28, Median +4.49%, Excess -0.23%, Beat mkt rate 39.3%

120 days after: historical avg +5.76%

20-day +0.82%
60-day +2.44%
120-day +5.76%
20-day
60-day
120-day
Win
60.7%
57.1%
71.4%
Sample
28
28
28
Median
+2.16%
+5.29%
+4.49%
Excess
+0.35%
+0.19%
-0.23%
Beat mkt rate
53.6%
53.6%
39.3%

Over 28 occurrences, 120-day forward avg gained 5.76%, lagged the market by 0.23 pts; win rate 71.4%.

Top-quintile 6-month momentum

Active · now 81.49%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
19 historical occurrences (since 2018-03-12)

Average forward return after Top-quintile 6-month momentum

20-day: Win 44.4%, Sample 18, Median -1.01%, Excess +0.46%, Beat mkt rate 44.4%

60-day: Win 44.4%, Sample 18, Median -1.12%, Excess -0.63%, Beat mkt rate 38.9%

120-day: Win 76.5%, Sample 17, Median +5.88%, Excess -2.41%, Beat mkt rate 41.2%

120 days after: historical avg +5.84%

20-day +1.19%
60-day +2.47%
120-day +5.84%
20-day
60-day
120-day
Win
44.4%
44.4%
76.5%
Sample
18
18
17
Median
-1.01%
-1.12%
+5.88%
Excess
+0.46%
-0.63%
-2.41%
Beat mkt rate
44.4%
38.9%
41.2%

Over 17 occurrences, 120-day forward avg gained 5.84%, lagged the market by 2.41 pts; win rate 76.5%.

EPS surprise beat

Active · now 11.76%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
30 historical occurrences (since 2016-04-26)

Average forward return after EPS surprise beat

20-day: Win 69%, Sample 29, Median +5.49%, Excess +3.2%, Beat mkt rate 62.1%

60-day: Win 82.8%, Sample 29, Median +6.89%, Excess +3.25%, Beat mkt rate 65.5%

120-day: Win 75.9%, Sample 29, Median +8.32%, Excess +2.03%, Beat mkt rate 65.5%

120 days after: historical avg +9.48%

20-day +4.38%
60-day +7.15%
120-day +9.48%
20-day
60-day
120-day
Win
69%
82.8%
75.9%
Sample
29
29
29
Median
+5.49%
+6.89%
+8.32%
Excess
+3.2%
+3.25%
+2.03%
Beat mkt rate
62.1%
65.5%
65.5%

Over 29 occurrences, 120-day forward avg gained 9.48%, beat the market by 2.03 pts; win rate 75.9%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 259+24.2% +24.4% 91.1% +22.7%
20-40 149+25.4% +29.8% 74.5% +3.3%
40-60 You are here163+21.3% +23.1% 84.7% +1.8%
60-80 414+22.3% +23.7% 91.8% +3.4%
80-100 457-1.5% -8% 39.2% -17.3%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 21.23, placing it in the 51.6 own-history percentile, inside the 40-60 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+5.5%
Win rate 64% Excess +7.6%
136d
Now
+16.1%
Win rate 91% Excess +3.7%
145d
+3.9%
Win rate 66.3% Excess -5.2%
641d
60-day momentum down
+13.8%
Win rate 84.7% Excess +9.5%
281d
+8.1%
Win rate 49.6% Excess -2.4%
226d
+5.3%
Win rate 54.9% Excess -4.9%
133d

Currently in “Middle × 60-day momentum up”: across 145 historical days, 120-day forward avg gained 16.1%, win rate 91%, beat the market by 3.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 times historically; 60-day forward avg +9.59%, win rate 100%, beating the market by +5.11 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.